BVF Inc. IL, an investment firm, has recently increased its stake in Axsome Therapeutics, Inc. by 21.4% during the first quarter of this year. This information was disclosed in its most recent filing with the Securities & Exchange Commission. BVF Inc. IL now holds approximately 2,131,100 shares of Axsome Therapeutics, making it the company’s third largest position and accounting for about 4.8% of its total holdings.
At the time of the filing, BVF Inc. IL’s stake in Axsome Therapeutics was valued at $131,446,000. This demonstrates a significant investment in the biopharmaceutical company and reflects BVF Inc. IL’s confidence in Axsome Therapeutics’ potential.
Axsome Therapeutics is primarily focused on developing innovative therapies for central nervous system (CNS) disorders within the United States market. The company’s current commercial product portfolio includes two notable treatments: Auvelity and Sunosi.
Auvelity is a medication that combines dextromethorphan and bupropion to act as a N-methyl-D-aspartate receptor antagonist with multimodal activity targeted at individuals suffering from major depressive disorder. Sunosi, on the other hand, is indicated for excessive daytime sleepiness in patients diagnosed with narcolepsy or obstructive sleep apnea.
By concentrating on addressing unmet needs within CNS disorders, Axsome Therapeutics aims to provide patients with effective treatment options that can significantly improve their quality of life.
BVF Inc. IL’s increased investment indicates its confidence in Axsome Therapeutics’ potential to further develop and bring these innovative therapies to market successfully. As investors continue to recognize the value of companies dedicated to improving treatments for CNS disorders, it will be interesting to observe how this development impacts both Axsome Therapeutics and BVF Inc. IL moving forward.
Investors and stakeholders alike should monitor future developments from both Axsome Therapeutics and BVF Inc. IL for a better understanding of the long-term implications of this increased stake in Axsome Therapeutics.
Axsome Therapeutics, Inc.
Updated on: 05/12/2023
Debt to equity ratio: Strong Buy
Price to earnings ratio: Strong Sell
Price to book ratio: Strong Buy
DCF: Strong Buy
ROE: Strong Sell
12:00 AM (UTC)
Date:05 December, 2023
|Analyst / firm||Rating|
Axsome Therapeutics Gains Attention from Institutional Investors and Analysts
September 12, 2023 – Axsome Therapeutics (NASDAQ:AXSM) is gaining attention from institutional investors and hedge funds as holdings of the stock undergo modifications. Bayesian Capital Management LP recently acquired a new stake in shares of Axsome Therapeutics during the first quarter, amounting to $452,000. Simultaneously, Deutsche Bank AG raised its position in the company’s stock by 35.0% during the same period, now holding 64,859 shares valued at $4,001,000. Additionally, Ensign Peak Advisors Inc increased its position by 5.9%, owning 9,950 shares worth $614,000 after purchasing an extra 550 shares. Moreover, Price T Rowe Associates Inc. MD saw a rise of 12.2% in its position during the first quarter and now holds16,249 shares estimated to be valued at $1,003,000. Finally, RTW Investments LP raised its position in Axsome Therapeutics by a substantial 26.9% during the first quarter and currently owns an impressive number of shares -3,780815- valued at an estimated $233,p21025 that were purchased over an additional period adding up to more than three-quarters (76.60%) of the total available stock owned by institutional investors and hedge funds.
The market has taken a keen interest in Axsome Therapeutics recently with several analyst reports discussing its performance. In particular,Bank of America revised their rating for Axsome Therapeutics from “underperform” to “neutral,” increasing their price target from $59.00 to $81.00 in their research report released on August8th.Equally important is William Blair’s reaffirmation of their “outperform” rating on shares of Axsome Therapeutics on August7th.Moreover,Piper Sandler upgraded their rating from “neutral” to “overweight” with a target price increase from $70.00 to $90.00 in their research report issued on the same date.Meanwhile, Mizuho reaffirmed a “buy” rating and assigned a target price of$100.00 on shares of Axsome Therapeutics as per their August 28th report.VNET Group also reiterated its rating on Axsome Therapeutics in their June22nd research report.Additionally, various investment analysts have given different ratings to the stock, with one analyst reporting a sell rating, two assigning a hold rating, and ten issuing buy ratings.Based on data obtained from Bloomberg.com,the overall consensus rating for the company stands at”Moderate Buy,” accompanied by an average target price of $103.25.
Trading for Axsome Therapeutics opened at $80.60 on Tuesday with its 50-day moving average recorded at$75.05andits 200-day moving average standing at$72.19.The company shows promise with a current ratio of 4.52 and quick ratio of 4.44.From low levels such as $38.87 to unprecedented highs like $91.29,Axsome Therapeutics has experienced quite a fluctuation within the past year.Currently sporting amarket capitalization of approximately$3.80 billion along with a PE ratio of -18.83 and an impressive betaof1.87,Axsome Therapeutics shows potential.
To further evaluate its performance, Axsome Therapeutics last released its quarterly earnings data onAugust7th,presenting ($1.00) earnings per share (EPS)for the quarter.This surpassed the consensus estimate of ($1.24) by posting an excess EPSof$0.24.Witha negative return on equity boasting 92:39%alongsidea negative net margin reflecting101:07%,Axsome Therapeutics proved itself worthy amidst challenging times.Additionally,during the quarter under review,the company achievedamulti-million-dollarrevenue of $46.70 million, surpassing the consensus estimate set at$40.19 million.Sell-side analystspredicted Axsome Therapeutics, Inc. to record -4.04 earnings per share for the current year.
Axsome Therapeutics has attracted significant interest from institutional investors and hedge funds due to its recent holdings modifications, making it a topic of discussion among analysts.The varying rating opinions signify the potential for growth that the stock possesses.Furthermore,the fluctuating trading valuesprovide hope to prospective investors.Axsome Therapeutics’ strong financial performance during the previous quarter also suggests good times ahead.With these developments and indicators in place,investorshave reason to be optimistic aboutAxsome Therapeutics’ future prospects as a company.